ATE397019T1 - Herstellung von f(ab')2 fragmenten in saügetierzelle - Google Patents

Herstellung von f(ab')2 fragmenten in saügetierzelle

Info

Publication number
ATE397019T1
ATE397019T1 AT02789019T AT02789019T ATE397019T1 AT E397019 T1 ATE397019 T1 AT E397019T1 AT 02789019 T AT02789019 T AT 02789019T AT 02789019 T AT02789019 T AT 02789019T AT E397019 T1 ATE397019 T1 AT E397019T1
Authority
AT
Austria
Prior art keywords
fragments
preparation
mammal cells
cells
antibody fragments
Prior art date
Application number
AT02789019T
Other languages
English (en)
Inventor
Abraham Bout
David Jones
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE397019T1 publication Critical patent/ATE397019T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624Disulfide-stabilized antibody (dsFv)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02789019T 2001-12-17 2002-12-17 Herstellung von f(ab')2 fragmenten in saügetierzelle ATE397019T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL0100917 2001-12-17

Publications (1)

Publication Number Publication Date
ATE397019T1 true ATE397019T1 (de) 2008-06-15

Family

ID=19760784

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02789019T ATE397019T1 (de) 2001-12-17 2002-12-17 Herstellung von f(ab')2 fragmenten in saügetierzelle

Country Status (11)

Country Link
US (2) US20050048038A1 (de)
EP (1) EP1456238B1 (de)
AT (1) ATE397019T1 (de)
AU (1) AU2002353662B2 (de)
CA (1) CA2470579C (de)
DE (1) DE60226896D1 (de)
DK (1) DK1456238T3 (de)
ES (1) ES2307807T3 (de)
NZ (1) NZ533332A (de)
SI (1) SI1456238T1 (de)
WO (1) WO2003051927A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
PT1465987E (pt) 2001-12-07 2008-04-15 Crucell Holland Bv Produção de vírus, isolados virais e vacinas
DK1456238T3 (da) 2001-12-17 2008-08-18 Crucell Holland Bv Produktion af F(ab')2-fragmenter i pattedyrceller
WO2004099396A1 (en) 2003-05-09 2004-11-18 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
WO2019070108A1 (es) 2017-10-02 2019-04-11 Laboratorios Silanes S.A. De C.V. Proceso de alto rendimiento para la producción de antivenenos de fragmentos f (ab') 2 de anticuerpos
WO2023205656A2 (en) * 2022-04-18 2023-10-26 John Paul Ii Medical Research Institute Immortalized cells for production of bioproducts, methods of producing bioproducts with an immortalized cell, and methods of making immortalized cells for production of bioproducts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
EP0173552B1 (de) * 1984-08-24 1991-10-09 The Upjohn Company Rekombinante DNA-Verbindungen und Expression von Polypeptiden wie tPA
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US7018809B1 (en) * 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
HK1048138B (zh) * 1999-04-15 2009-06-12 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
EP1103610A1 (de) * 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
EP1130099A1 (de) * 2000-02-25 2001-09-05 Crucell Holland B.V. Aktiviertes Vitronektin als Angiogenesemarker nachgewiesen durch Phagen-Antikörper
DK1456238T3 (da) 2001-12-17 2008-08-18 Crucell Holland Bv Produktion af F(ab')2-fragmenter i pattedyrceller

Also Published As

Publication number Publication date
WO2003051927A3 (en) 2003-11-20
US7537916B2 (en) 2009-05-26
NZ533332A (en) 2005-07-29
ES2307807T3 (es) 2008-12-01
CA2470579C (en) 2012-03-06
EP1456238A2 (de) 2004-09-15
SI1456238T1 (sl) 2008-08-31
CA2470579A1 (en) 2003-06-26
WO2003051927A2 (en) 2003-06-26
US20080166767A1 (en) 2008-07-10
DE60226896D1 (de) 2008-07-10
US20050048038A1 (en) 2005-03-03
DK1456238T3 (da) 2008-08-18
AU2002353662A1 (en) 2003-06-30
EP1456238B1 (de) 2008-05-28
AU2002353662B2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
EP1362093A4 (de) Schnellproduktion monoklonaler antikörper
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
ATE397019T1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
DK1443961T3 (da) Glycoprotein-sammensætninger
IL162648A0 (en) Cellular compositions and methods of making and using them
BR0015224A (pt) Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
ATE500323T1 (de) Subtilisin-variante
TR199801179T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
AR032394A1 (es) Una composicion oral.
BR0109346A (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
NL300754I2 (de)
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
BR0215266A (pt) Preparação liofilizada compreendendo anticorpos contra o receptor de egf
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
PT1200561E (pt) Clone celular recombinante estavel, sua producao e utilizacao
NO20061470L (no) Fremgangsmate for fremstilling av gamma-karboksylerte proteiner
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
WO2002022573A3 (en) Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
DK1517694T3 (da) Planteekstrakter
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
BR0013221A (pt) Chá preto de folha
DE60107718T8 (de) Konservierung von zellen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1456238

Country of ref document: EP